Clinical Trial Update: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) [Phase 3]

View source ↗

Summary

This is a Phase 3 randomized trial evaluating Intismeran Autogene (V940) plus pembrolizumab versus placebo plus pembrolizumab in non-small cell lung cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Intismeran Autogene (V940) (V940)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING